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Abstract
Leishmaniasis, a neglected disease caused by protozoans of the Leishmania genus, is still 
present in 98 countries with about two million new cases yearly worldwide. It is trans‐
mitted by female phlebotomine sandflies and presents itself as cutaneous, mucocutane‐
ous and visceral clinical forms, depending on the Leishmania species and the parasite‐host 
relationship. Visceral leishmaniasis (VL) is caused by Leishmania (Leishmania) infantum 
chagasi, endemic in 12 countries of Latin America, with 90% of the cases reported in 
Brazil. VL is characterized by irregular bouts of fever, weight loss, hepatosplenomegaly 
and pancytopenia, being highly fatal with no treatment. The main strategy in limiting 
the expansion of VL, besides the treatment of human cases, is the control of the vector 
Lutzomyia longipalpis and its reservoirs. There are only few studies on the natural infection 
of Leishmania species, especially in relation to its endemic distribution. Epidemiological 
studies of leishmaniasis may indicate the infection rate of parasites in sandflies in order 
to assess the populations at risk and to direct public health control strategies. In this con‐
text, we aimed to review the main features of VL with regard the distribution of disease 
cases and natural infection rates of Leishmania in Lu. longipalpis in Latin America.
Keywords: visceral leishmaniasis, natural infection, Lu. longipalpis, phlebotomine, 
Leishmania (Leishmania) infantum chagasi
1. Introduction
Leishmaniasis is a protozoan disease caused by the Leishmania genus, transmitted by female 
phlebotomine sandflies. Foxes and didelphid marsupials are the main rural reservoirs, and 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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domestic dogs the principal reservoir in urban areas [1]. The introduction in urban settings is 
due to multiple conditions such as migrations, inadequate living conditions, high population 
density and environment changes [2].
The disease presents itself in different clinical forms including cutaneous (CL), mucocuta‐
neous (MCL) and visceral leishmaniasis (VL), depending on the species of Leishmania and 
the parasite‐host relationship. In Latin America, VL is caused by the protozoan Leishmania 
(Leishmania) infantum chagasi and is the most severe form, characterized by intermittent fever, 
weight loss, hepatosplenomegaly and pancytopenia [3].
Since VL is no longer being characterized as a rural disease (1980s), [3] the main strategy to 
limit the expansion of the disease, besides the treatment of human cases, is the control of the 
vector Lutzomyia longipalpis and the parasite's reservoirs. In addition, molecular epidemiologi‐
cal studies of natural infection with species of Leishmania, especially in relation to its endemic 
distribution, may indicate the infection rate of parasites in sandflies in order to assess the 
populations at risk and to direct public health control strategies. In this context, we aimed in 
this chapter to review the main features of VL with regard the distribution of disease cases 
and natural infection rates of Leishmania in phlebotomine females in Latin America.
2. Leishmaniasis
Leishmaniasis is one of the most neglected diseases, present in at least 88 countries across 
the tropical and subtropical regions of Africa, Asia, Mediterranean, South Europe as well as 
South and Central Americas, with a global distribution of about two million new cases yearly 
worldwide [4]. The disease poses a great impact in public health contributing to 3.3 million 
disability adjusted life years [5]. It is a parasitic disease caused by the biphasic protozoan of 
the family Trypanosomatidae, order Kinetoplastida and genus Leishmania, which includes 
35 species, being at least 13 of them considered human pathogens [6] (Figure 1).
Figure 1. Main species of the Leishmania genus. Those causing visceral leishmaniasis (VL): Leishmania (L.) donovani in 
Asia, Leishmania (L.) chagasi in the Americas and Leishmania (L.) infantum in Asia, Europe and Africa. Note: Leishmania 
(L.) infantum chagasi nomenclature was proposed by Marcili et al. [7] using phylogenetic analysis of Leishmania species 
occurring in Latin America.
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Leishmania is transmitted by the bite of infected female sandflies of the Phlebotominea 
subfamily of the genus Phebotomus in the Old World and the genus Lutzomyia in the New 
World [8]. Sandflies become infected during blood meals by ingesting leishmanial amas‐
tigotes of infected cells. Amastigotes differentiated into dividing promastigotes (flagellate 
forms) to establish the parasite life cycle and multiplying in the gut of sandfly vector (in 
the hindgut and in the midgut for Viannia and Leishmania subgenus, respectively) [9, 10]. 
After digestion of the blood meal, successful infection in a sandfly vector results in the 
development of several promastigotes forms, named according to their morphology as pro‐
cyclic, haptomonad, nectomonad, paramastigote and metacyclic forms. Only metacyclic 
forms transmitted through sandfly bites are able to begin an infection in vertebrate hosts, 
and thereby the transmission cycle completes [11, 12]. Thus, during blood meals, the vector 
injects the infective promastigotes in the host, which induce chemotaxis of neutrophils and 
macrophages. The parasites are then engulfed by macrophages and other types of mono‐
nuclear and polymorphonuclear phagocytic cells, becoming amastigotes, which is the tissue 
stage. Inside the cell, the amastigotes reproduce by binary fission, breakup the cell and are 
released to extracellular environment, being again engulfed by phagocytic cells and repeat‐
ing the cycle [13–16] (Figure 2).
Figure 2. Life cycle of Leishmania spp. Leishmania parasites are transmitted by the bites of infected female sandflies during 
their blood meals. The vector injects the metacyclic promastigote forms, which are engulfed by phagocytic cells at the bite 
site. Inside the cells, promastigotes transform into amastigotes, the tissue stage of the parasite, which will then reproduce 
by binary fission and progress to infect other mononuclear phagocytic cells. Interactions between parasite, host and 
other factors will determine whether the infection progress to cutaneous or visceral leishmaniasis. Sandflies become 
infected by ingesting infected cells during blood meals. In the digestive tract of the vector, amastigotes differentiate into 
promastigotes and migrate to the proboscis, from where they are injected into the hosts during the bite.
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Leishmaniasis in humans presents a wide diversity of clinical manifestations depending on 
the complex interactions between the parasite and the host immune responses, ranging from 
asymptomatic to severe and potentially lethal disease. The disease is classified into three main 
forms: cutaneous (CL), mucocutaneous (MCL), and visceral leishmaniasis (VL) [17].
CL is the most frequent clinical form, representing 75% of leishmaniasis total cases, and 
has an estimated yearly incidence of 0.7–1.2 million cases, being distributed in Afghanistan, 
Colombia, Brazil, Algeria, Peru, Costa Rica, Iran, Syria, Ethiopia and Sudan [4, 5]. CL is char‐
acterized by localized cutaneous nodules or lesions at the site of the sandfly bite (localized 
form). It has an incubation time of weeks to months, and initially has the appearance of an 
erythematous papule, which can evolve into a plaque or ulcer or can spontaneously heal 
in 2–10 months. These lesions are usually painless and without evident systemic symptoms 
or pruritus. Parasites can disseminate through the skin and form multiple non‐ulcerative 
nodules (diffuse form), which is associated to an ineffective immune response, especially in 
patients infected with human immunodeficiency virus (HIV) [18, 19].
Moreover, Leishmania spp. can propagate through the lymphatic system, resulting in naso‐
bronchial and oral mucosal tissue destruction (MCL form) [18, 19]. The MCL form affects 
both nasal and oral mucous membranes, leading to partial or total destruction. The VL is a 
systemic and chronic disease, and it is highly fatal if not treated [1].
3. Visceral leishmaniasis
3.1. Epidemiology
VL is recognized by the World Health Organization (WHO) as one of the most important 
 zoonoses, due to its high incidence and mortality. Every year about 500,000 new cases of VL are 
reported, with 40,000–50,000 deaths worldwide [20]. The disease is endemic in 65  countries, 
including Bangladesh, India, Brazil, Nepal, Ethiopia and Sudan. In Latin America, VL is pres‐
ent in 12 countries and is caused by the protozoan Leishmania (L.) infantum chagasi, with 90% 
of the cases being reported in Brazil, especially in the Northeast and Southeast regions, rep‐
resenting a significant public health concern [3, 21]. In Brazil, the average number of cases of 
VL increased from 2866 in 1990–2000 to 3353 in 2001–2014 [22], with a fatality rate of about 
7% in 2014 [23].
The disease has shown significant changes in the pattern of transmission, initially with a 
predominantly rural distribution, which fly has expanded to peri‐urban and large urban 
areas [20, 24]. Although the main route of transmission is associated to hematophagous sand‐
fly vectors, there are other routes which are important to be reported, including sexual, verti‐
cal and hematogenic [16].
Although the infection can affect people of all ages, in endemic areas, most reported cases 
are children below 10 years old. This is probably due to their immunological immaturity 
aggravated by malnutrition, which is common in these areas [3, 20]. Over 60% of the affected 
people are males [21, 25].
The Epidemiology and Ecology of Leishmaniasis62
3.2. Clinical features
VL is also known as kala‐azar or “black fever/disease”, which is a reference to the skin hyper‐
pigmentation by melanocyte stimulation during infection. In addition, other terms are used 
to describe VL, such as Dumdum fever, Assam fever and infantile splenomegaly. It is the 
most severe leishmaniasis form and generally affects the spleen, liver, bone marrow or other 
lymphoid tissues. The syndrome is characterized by fever, weight loss, hepatosplenomegaly, 
pancytopenia and hypergammaglobulinemia. The fever can be continuous or remittent, and 
also characteristically described as periods with and without pyrexia, becoming intermittent 
at a later stage. Patients may also report night sudoresis, weakness, diarrhea, malaise and 
anorexia [26].
The onset of VL can be insidious or sudden, and the incubation period varies from 3 to 
6 months, depending on the patient’s age and immune status, as well as the species of 
Leishmania. If untreated, it is frequently fatal within 2 years. Death may be related to hem‐
orrhage, severe anemia, immunosuppression and/or secondary infections. Interestingly, 
some successfully treated VL cases may develop maculopapular or nodular rashes, named 
post‐kala‐azar dermal leishmaniasis [17, 19] and classified into three types: depigmented 
macules, erythematous patches, and yellowish pink nodules [27]. Complications of VL 
include amyloidosis, glomerulonephritis [28] and cirrhosis [29]. In HIV patients coinfected 
with VL, atypical symptoms include gastrointestinal ulcerations, pleural effusion and ody‐
nophagia [30].
3.3. Diagnosis and treatment
The diagnosis of VL is still a challenge, especially in needy regions. Even though serological 
and molecular tests have improved the laboratory diagnosis of VL considerably, none of the 
available methods present 100% sensitivity and specificity [31]. The gold standard diagnosis 
method is still the identification of the parasite, with visualization of amastigotes from bone 
marrow or visceral aspirates, which holds 100% specificity. However, the sensitivity of the 
parasitological test varies depending on the sample, and aspirations are invasive and can 
cause life‐threatening hemorrhages. Serological methods, on the other hand, are highly sensi‐
tive but with varying specificity [32], showing cross‐reactivity with trypanosomiasis, malaria, 
tuberculosis, brucellosis and typhoid fever [31]. In addition, antileishmanial antibodies can be 
found in asymptomatic individuals and are still present after treatment and recovery, making 
the evaluation of therapeutic response difficult [33, 34]. Molecular techniques are remarkably 
sensitive and specific and can differentiate asymptomatic from clinically active infection even 
in HIV coinfected patients, but are costly [35, 36].
The first choice of treatment for VL is the antimonial N‐methyl glucamine followed by 
amphotericin B (AmpB) and derivatives [37] (Table 1). The AmpB isolated in 1955 as a natural 
antibiotic was first reported as having antileishmanial activity in the early 1960s. Currently, 
its liposomal formulation is used to treat VL with a 95% cure rate for a single‐course 
 therapy [38, 39]. Although there are no absolute contraindications against the use of AmpB, 
nephrotoxicity [40] and hematotoxicity [41] should be considered [42].
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The liposomal form of AmpB is ideal in the treatment of leishmaniasis, since enables the drug to 
concentrate specifically at the site of infection, reducing the concentration in  others organs [43, 44]. 
More recently, other drugs such as miltefosine, paromomycin and pentamidine have been used 
in the treatment of VL in some countries of Africa and Asia, but the efficacy and required dosage 
of several of these medicines have not been demonstrated in all endemic areas and may differ 
between these areas [20].
Some criteria need to be observed for the choice of treatment, such as assessment and stabili‐
zation of clinical conditions and comorbidities present at the diagnosis of VL and electrocar‐
diogram. The use of methylglucamine antimoniate has been especially critical in cases where 
resistance against pentavalent antimonials is widely spread [45].
Unfortunately, the majority of the population affected by VL is of low income, having no 
access to diagnosis and treatment options, thereby increasing the mortality rate due to the 
infection. In endemic areas, VL diagnosis is in most cases based only on clinical characteristics 
and epidemiologic aspects. Despite the urgent needs, research and development on leish‐
maniasis have been regrettably neglected.
4. Natural infection of phebotomine with Leishmania
4.1. Vectors of L. (Leishmania) infantum chagasi
According to Killick‐Kendrick [47], four criteria must be fulfilled before incriminating a given 
specie as a vector for a zoonotic disease: feeding on humans and in the animal reservoir, 
supporting the parasites after ingestion, displaying indistinguishable parasites from those 
isolated from patients and transmitting the parasite by biting.
Lutzomyia (Lutzomyia) longipalpis is the most competent vector for L. (L.) infantum chagasi in VL 
Latin American foci; however, other sandflies species may be acting in the cycle of VL, mainly 
in areas where Lu. longipalpis is absent [48, 49]. In fact, Pintomyia (Pifanomyia) evansi has been 
related to VL transmission in Colombia [50–53] and Venezuela [54, 55].
Medication Molecular formula Presentation Dose/route administration
Antimonial 
N‐methylglucamine
C
7
H
20
NO
9
Sb Pentavalent antimony (Sb+5) 
Ampoules 5 mL (300 mg/mL)
20 mg/Sb+5/kg/day, once daily, 
endovenosa or intramuscular for 
30 days. Max dose of 3 ampoules 
per day.
Amphotericin B C
47
H
73
NO
17
Amphotericin B deoxycholate
Bottle with 50 mg (lyophilized)
1 mg/kg/day by infusion for 
14–20 days*.
Liposomal amphotericin B C
47
H
73
NO
17
Bottle/ampoule with 50 mg 
(lyophilized)
3 mg/kg/day by infusion for 
7 days or 4 mg/kg/day for 5 days 
single dose.
* The duration of treatment should be based on clinical outcome, considering the speed of response and the presence 
of comorbidities.
Source: Ministério da Saúde [46].
Table 1. Medvications for treatment of VL according to molecular formula, presentation, dose and route of administration 
recommended in Brazil.
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Other reports from Argentina and Brazil associated the presence of Migonemyia migo-
nei with autochthonous cases of VL [49, 56, 57]. Recent studies using quantitative poly‐
merase chain reaction (qPCR) [58] and experimental infection [59] confirmed Mg. migonei 
as a potential vector of VL in Latin America. In addition, Nyssomyia antunesi [60] and Lu. 
(Lutzomyia) cruzi [61] were found naturally infected with L. chagasi in Brazil. Montoya‐
Lerma et al. [62] observed an association between Pi. evansi and L. (L.) infantum chagasi 
infection, and indicated that Pi. evansi represents a potential vector for VL in Colombia 
and Venezuela.
Evidence of transmission of VL by Lu. cruzi in the area of Jaciara, State of Mato Grosso in 
Brazil was confirmed by Missawa et al. [63]. Lu. cruzi and Lu. (Lutzomyia) forattinii are potential 
VL vectors in the area of Corumbá (Brazil), where notifications of the disease in humans and 
dogs have increased over the last two decades [64].
CL vectors such as Nyssomyia neivai were found infected with L. (L.) infantum chagasi in the 
city of Florianópolis (in the South region of Brazil) [65] and in an urban area of Minas Gerais 
state (in the Central region of Brazil), with no records of human VL and no data available for 
canine VL [66]. Similarly, as observed in Brazil, natural infection of Mg. migonei and Nyssomyia 
whitmani were found in Argentina [67].
Note: The classification and abbreviation of sandflies were used here according to Galati [68] 
and Marcondes [69], respectively.
4.2. Methods for detecting naturally infected vectors
The report of natural infection by L. (L.) i. chagasi in female phlebotomine sandflies is an 
important tool for epidemiological investigation, being indispensable for appropriate VL con‐
trol strategy. Distinct techniques have been applied to identify parasitic infection in the insect, 
including classical and molecular methods.
The classical method to detect natural infection is based on the direct observation of parasites 
under microscopy, after sandfly gut dissection. However, this in loco identification is labori‐
ous, time consuming and requires experience. Another limiting factor is the difficulty in pro‐
cessing the large number of samples required in epidemiological studies [70, 71]. In  addition, 
since other flagellated parasites can be found in the digestive tract of the insects, infection 
needs to be confirmed by in vitro culture of Leishmania or by inoculation into laboratory 
 animals [72, 73]. Furthermore, low parasitemia may underestimate the rates of natural sand‐
fly infection, which are usually about 0.2% using the classical approach, often contrasting 
with the high frequency of VL in endemic areas [64, 74–76]. However, the dissection method 
has the advantage of allowing to determine the course and location of infection by Leishmania 
in the sandfly digestive tract [77].
Alternatively, molecular approaches represent a more specific and sensitive technique, allow‐
ing the DNA detection of a single Leishmania parasite, regardless of its stage and localiza‐
tion in the insect gut [78, 79]. Indeed, PCR‐based technique was eight times more efficient 
in detecting trypanosomatids than the dissection method and two times more efficient in 
identifying natural infection by Leishmania [80]. However, molecular methods have the dis‐
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advantage of not being able to distinguish between viable and dead parasites [81]. To access 
the genetic material of the parasite, DNA/RNA is extracted generally using a pool of about 
10 female phlebotomine sandflies [82, 83].
Multiple molecular markers from nuclear and kinetoplast Leishmania DNA have been used 
to detect naturally infected phlebotomines, including the miniexon‐derived RNA gene, 
rRNA gene, repeated genomic sequences and the kinetoplast minicircle DNA (kDNA), 
which is present at thousands of copies per cell [84–87]. These molecular markers are 
assessed by PCR methods using specific primers to amplify conserved regions, with kDNA 
amplification having greater reliability as a marker for the parasite when compared to 
miniexon and 18S rRNA [88]. Currently, PCR assays are able to detect and identify the 
parasite (L. (L.) i. chagasi) and vector (Lu. longipalpis) responsible for VL [82, 89–91]. Besides 
that, qPCR combines the identification of genetic material with the quantification of para‐
sites present in the phlebotomine, which is important for VL transmission and the estab‐
lishment of infection [83].
4.3. Disease cases and natural infection rates in Latin America
The magnitude of VL in Latin America is not completely known, mainly because most coun‐
tries do not have effective surveillance systems [92–94]. VL was reported in at least 12 coun‐
tries in Latin America, with Brazil having the highest number of cases, followed by Paraguay, 
Argentina and Colombia [21, 25] (Figure 3).
The Brazilian Ministry of Health declared a total of 78,444 VL cases in 25 years of notifica‐
tion (1990–2014), with approximately 67% of them in the Northeast region. In this period, the 
annual mean in the country was 3137 cases and the incidence was two cases/100,000 inhabit‐
ants [22]. In addition, an increase of 3.2–6.6% in mortality rate caused by leishmaniasis was 
reported in Brazil from 2000 to 2014 [23].
Although resources have been invested in the VL control and establishment of protocols for 
specific treatment, important territorial expansion of VL in Latin America countries has been 
registered [21, 25, 95]. In Brazil, it was initially restricted to poor rural areas in the northeast 
Figure 3. Visceral leishmaniasis cases in four Latin American countries: Brazil, Paraguay, Colombia and Argentina 
(2001–2013). Source: PAHO/WHO [21, 25].
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of the country; however, since 1980s, the disease has gradually spread to major cities and 
peri‐urban areas in North, Southeast, South and Midwest regions [3, 96], occurring in 23 of 
the 27 Brazilian states [97] (Figure 4).
Current control strategies to limit the VL expansion are directed against the vector, using 
insecticides; the canine reservoir by serological screening, by euthanasia in seropositive dogs 
and by the use of vaccine in asymptomatic animals with negative serological results, in addi‐
tion to the diagnosis and treatment of human cases. Unfortunately, the results of those inter‐
ventions have been shown to be modest [3, 96]. Since VL epidemiological data are generally 
based only on the prevalence of human infection [98], surveillance strategies based on a better 
definition of transmission, risk areas and rates of naturally infected sandflies are necessary in 
order to provide better control of the disease.
Natural infection rates by L. (L.) i. chagasi in phlebotomine are still poorly investigated even in 
VL endemic areas (Table 2). Literature has shown that infection ratios are usually low, rang‐
ing around 1–3% in Latin America, often contrasting with the high incidence of the disease in 
these regions [74, 76, 99].
Figure 4. Distribution of visceral leishmaniasis cases in Latin America countries in 2013. Source: PAHO/WHO [97].
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According to Cimerman and Cimerman [109], transmission depends on the presence of high 
densities of Lu. longipalpis, as observed during outbreaks of the disease. Several factors may 
be associated with the difference between natural infection rates detected and VL human 
cases reported. However, it is possible that even low infection rates are sufficient to maintain 
Locality Specimens (N) Technique Infection rates (%) Period of collect Reference
Brazil
North region
Pará, Barcarena 280 PCR 5.3–8.6 Nov 2003–Feb 2004 [88]
Pará, Barcarena 1451 Dissection 0.0 Oct–Dec 2007, Feb 
2008 and Jan 2009
[100]
Northeast region
Maranhão, São Luís Island 800* PCR 0.25–1.25 Mar–Aug 2005 [101]
Maranhão, Raposa 448* PCR 1.56 Aug 2006–Jul 2008 [98]
Piauí, Teresina 1832 Dissection 1.1 Feb 2004–Jan 2005 [102]
Ceará, Fortaleza 1220* PCR 3.7 Feb 2009–Jan 2010 [83]
Midwest region
Mato Grosso, Várzea Grande 420* PCR 0.71 Jul 2004–Jun 2006 [99]
Mato Grosso do sul, Campo 
Grande
105* PCR 1.9 Oct 2005–Sep 2006 [103]
Mato Grosso do Sul, 
Antônio João
81* PCR 3.9 No data [86]
81 Dissection 1.24 No data [86]
Southeast region
Minas Gerais, Belo Horizonte 245* PCR 19 Jul 2006–Jun 2007 [104]
245 Dissection 1.22 Jul 2006–Jun 2007 [104]
Minas Gerais, Janaúba 1550* PCR 3.9 Apr 2006–Mar 2007 [105]
Colombia
Santander, Piedecuesta 1138* PCR 1.93 May 1999–Sep 2000 [106]
El Callejon 681 Dissection 0.59 1986–1988 [107]
Venezuela
Aragua, Guayabita 353 Dissection 0.28 Jan 1993–Jun 1994 [55]
Bolivia
La Paz, Los Yungas 2578 Dissection 2.2–4.2 Oct–Nov 1982 [108]
Argentina
Misiones, Posadas 211* PCR 0.47 Jan–Feb 2009 [82]
Note: * Lu. longipalpis females evaluated in pools.
Table 2. Natural infection ratios by Leishmania (L.) chagasi in Lu. longipalpis females in Latin America.
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 circulating infection, highlighting the importance of monitoring sandfly vectors in order to 
prevent the occurrence of VL, as well as for the definition of risk areas.
On the other hand, high rates of natural infection were observed by Freitas‐Lidani et al. [88] and 
Saraiva et al. [104], with 8.6 and 19%, respectively, in Pará and Minas Gerais states (North and 
Southeast regions of Brazil). Both rates were determined using molecular approaches by indi‐
vidual vector analysis. The local incidences of VL for the same period were 281 (Pará state, 
Brazil) and 407 (Minas Gerais state, Brazil) cases [22], respectively. Although the assessment 
of individual vectors may be more laborious, the great advantage over pooled samples is the 
achievement of more informative rates of infected sandflies, especially in areas where new 
cases are beginning to emerge in dogs and humans.
5. Conclusion
The epidemiology of leishmaniasis is complex due to the diversity of protozoan, vector and 
reservoirs species, associated to a variety of clinical events. Early diagnosis and treatment 
of infected patients is crucial to direct public policies of VL control, especially because the 
disease has common clinical manifestations and geographic distributions with other infec‐
tions such as Chagas disease, malaria, schistosomiasis, typhoid fever and tuberculosis. In this 
context, molecular approaches to determine rates of Lu. longipalpis naturally infected with 
Leishmania allows the estimation of the transmission risk for VL and vectorial capacity in areas 
where many species of phlebotomine sandflies coexist.
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